Niemann-Pick Disease Type C (NPC) Market Expected to Witness Robust Growth Through 2036, Driven by Novel Disease-Modifying Therapies and Improving Diagnostic Capabilities | DelveInsight

The Niemann-Pick Disease Type C (NPC) market is projected to witness substantial growth across the seven major markets (7MM) during the forecast period (2022-2036), supported by increasing disease awareness, advances in genetic and biomarker-based diagnosis, and the emergence of innovative disease-modifying therapies. The treatment landscape is evolving rapidly with therapies such as TRAPPSOL CYCLO, Nizubaglustat, AQNEURSA, and MIPLYFFA, which are expected to significantly improve clinical outcomes for patients with this ultra-rare lysosomal storage disorder.

DelveInsight's "Niemann-Pick Disease Type C (NPC) Market Insight, Epidemiology, and Market Forecast-2036" provides a comprehensive assessment of disease epidemiology, current treatment practices, marketed products, emerging therapies, patient journey, market trends, pricing, reimbursement, and commercial opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The report offers detailed insights into historical and forecasted market performance, competitive landscape, drug uptake projections, regulatory developments, and key market dynamics influencing the future NPC treatment ecosystem. It also evaluates unmet clinical needs and highlights the impact of late-stage pipeline therapies expected to reshape the market over the coming decade.

To know in detail about the Niemann-Pick Disease Type C (NPC) market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here;
https://www.delveinsight.com/sample-request/niemann-pick-disease-type-c-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Niemann-Pick Disease Type C (NPC) Market Report

• The NPC market is expected to grow considerably through 2036, driven by increasing diagnosis, improved understanding of disease biology, and the anticipated launch of multiple disease-modifying therapies.
• Niemann-Pick Disease Type C is a rare, progressive lysosomal storage disorder caused by NPC1 or NPC2 gene mutations, resulting in impaired intracellular lipid trafficking and accumulation of cholesterol and glycosphingolipids in the brain, liver, spleen, and other tissues.
• Over the past decade, advances in genetic testing, biomarker assays, and next-generation sequencing have contributed to increased disease awareness and improved diagnosis, although delayed diagnosis remains a major clinical challenge.
• In 2025, there were approximately 1,000 diagnosed prevalent cases of NPC across the 7MM, emphasizing the ultra-rare nature of the disease.
• The treatment landscape is expanding with recently approved therapies including AQNEURSA (levacetylleucine) and MIPLYFFA (arimoclomol), alongside promising late-stage investigational candidates such as TRAPPSOL CYCLO and Nizubaglustat.
• The report estimates that the NPC market size in the 7MM will increase substantially during the forecast period, supported by higher diagnosis rates, expanding therapeutic options, and increased uptake of novel therapies.

Key Factors Driving the Niemann-Pick Disease Type C (NPC) Market

Advancements in Diagnostic Technologies: Increasing adoption of plasma biomarkers, genetic sequencing, and advanced molecular diagnostics is enabling earlier and more accurate diagnosis of NPC, improving patient identification and treatment initiation.

Emergence of Disease-Modifying Therapies: The advancement of innovative therapies such as TRAPPSOL CYCLO, Nizubaglustat, AQNEURSA, and MIPLYFFA is expected to transform disease management by targeting the underlying pathology rather than solely controlling symptoms.

Growing Rare Disease Research: Continued investment in lysosomal storage disorders, precision medicine, and orphan drug development is accelerating clinical research and expanding therapeutic opportunities for patients with NPC.

Supportive Regulatory Environment: Regulatory incentives including Orphan Drug Designation, expedited development pathways, and increasing regulatory support for rare diseases continue to encourage innovation and commercialization of novel NPC therapies.

Niemann-Pick Disease Type C (NPC) Market Analysis

Management of Niemann-Pick Disease Type C requires a multidisciplinary approach involving neurologists, pediatricians, geneticists, hepatologists, ophthalmologists, pulmonologists, rehabilitation specialists, and other healthcare professionals. Current management combines supportive care with therapies aimed at slowing neurological progression, including miglustat, AQNEURSA, and MIPLYFFA. Emerging therapies such as TRAPPSOL CYCLO and Nizubaglustat have demonstrated encouraging clinical potential and are expected to further expand treatment options. Improvements in diagnostic capabilities, greater disease awareness, and the anticipated approval of additional disease-modifying therapies are expected to drive sustained growth of the NPC market through 2036.

Get a Free sample for the Niemann-Pick Disease Type C (NPC) Market Forecast, Size & Share Analysis Report: Niemann-Pick Disease Type C (NPC) Market Forecast

Niemann-Pick Disease Type C (NPC) Competitive Landscape

The Niemann-Pick Disease Type C (NPC) treatment landscape is evolving rapidly with the introduction of newly approved therapies and the continued advancement of disease-modifying pipeline candidates. Historically, NPC treatment has relied largely on supportive care and symptomatic management, but recent regulatory approvals and late-stage clinical programs are transforming the therapeutic outlook. Companies are increasingly focusing on therapies that target the underlying defects in intracellular cholesterol transport and lipid metabolism rather than simply alleviating neurological symptoms.

Key companies shaping the competitive landscape include IntraBio, Zevra Therapeutics, Cyclo Therapeutics, Azafaros, and Beren Therapeutics, with several therapies progressing through regulatory review and late-stage clinical development.

AQNEURSA (levacetylleucine): IntraBio
AQNEURSA is an orally administered small molecule that modulates calcium channels and normalizes cellular energy metabolism. It is approved for the treatment of neurological manifestations of NPC in adults and pediatric patients. In September 2024, the therapy received US FDA approval, followed by European Commission marketing authorization in January 2026. Clinical data demonstrated statistically significant improvement in neurological function with a favorable safety profile and no drug-related serious adverse events reported.

MIPLYFFA (arimoclomol): Zevra Therapeutics
MIPLYFFA is the first therapy approved for use in combination with miglustat for treating neurological manifestations of NPC in patients aged two years and older. The therapy has demonstrated effectiveness in slowing disease progression and represents an important advancement in disease management. Ongoing regulatory activities continue to expand its global commercial potential.

TRAPPSOL CYCLO (Hydroxypropyl β-cyclodextrin): Cyclo Therapeutics
TRAPPSOL CYCLO is a specialized formulation of hydroxypropyl β-cyclodextrin designed to restore intracellular cholesterol transport by facilitating the removal of cholesterol trapped within lysosomes. The therapy is currently undergoing Phase III clinical development and has demonstrated encouraging clinical outcomes in pediatric NPC patients, supporting its potential as a disease-modifying treatment.

Nizubaglustat: Azafaros
Nizubaglustat is an orally available, brain-penetrant small molecule that modulates lipid metabolism and aims to reduce the accumulation of harmful lipids within lysosomes. The therapy has received US FDA Orphan Drug Designation for NPC and entered global Phase III clinical studies during 2025, positioning it among the leading late-stage pipeline candidates for Niemann-Pick Disease Type C.

Adrabetadex: Beren Therapeutics
Adrabetadex is being developed for infantile-onset NPC and represents another promising late-stage therapy. Its New Drug Application (NDA) has been accepted for FDA review, further strengthening the regulatory pipeline for disease-modifying NPC therapies.
Discover more about therapies set to grab major Niemann-Pick Disease Type C (NPC) market share @ Niemann-Pick Disease Type C (NPC) Treatment Landscape

Recent Developments in the Niemann-Pick Disease Type C (NPC) Treatment Landscape

• In March 2026, Beren Therapeutics presented new clinical data supporting the efficacy of Adrabetadex for infantile-onset NPC at the 2026 ACMG Clinical Genetics Meeting, including disease progression, survival, and biomarker findings.
• In February 2026, the US FDA accepted the NDA for Adrabetadex for infantile-onset NPC, assigning a PDUFA target action date of August 17, 2026.
• In January 2026, the European Commission granted marketing authorization for AQNEURSA (levacetylleucine) following a positive recommendation from the EMA's Committee for Medicinal Products for Human Use (CHMP).
• In September 2025, Rafael Holdings presented Phase III TransportNPC data demonstrating stabilization or improvement among pediatric NPC1 patients treated with TRAPPSOL CYCLO.
• In July 2025, Azafaros initiated two global Phase III clinical studies evaluating Nizubaglustat in NPC and GM1/GM2 gangliosidoses.
• In September 2024, the US FDA approved AQNEURSA as the first stand-alone therapy for neurological manifestations of NPC and approved MIPLYFFA for use with miglustat in patients aged two years and older.

What is Niemann-Pick Disease Type C (NPC)?

Niemann-Pick Disease Type C (NPC) is a rare, progressive lysosomal storage disorder caused by mutations in the NPC1 or NPC2 genes. These mutations impair intracellular cholesterol trafficking, resulting in toxic accumulation of cholesterol and glycosphingolipids within lysosomes, particularly in the brain, liver, and spleen. The disease presents with a broad spectrum of neurological and systemic manifestations, including ataxia, hepatosplenomegaly, cognitive decline, psychiatric symptoms, cataplexy, dysphagia, and vertical supranuclear gaze palsy. Diagnosis begins with clinical suspicion and is supported by plasma biomarkers such as oxysterols, lyso-SM-509, and bile acid derivatives, followed by confirmatory NPC1/NPC2 genetic testing. Despite advances in diagnostics, approximately 12-15% of suspected cases remain genetically inconclusive, contributing to diagnostic delays.
Niemann-Pick Disease Type C (NPC) Epidemiology Segmentation

The report provides detailed epidemiological analysis across the 7MM for the study period 2022-2036, including:
• Total Diagnosed Prevalent Cases of NPC
• Prevalent Cases of NPC
• Age-specific Cases of NPC
• Gender-specific Cases of NPC
• Mutation-specific Cases of NPC (NPC1 and NPC2)
• Total Treated Cases of NPC
• Epidemiology in the United States
• Epidemiology in EU4 and the United Kingdom
• Epidemiology in Japan

Download the report to understand which factors are driving Niemann-Pick Disease Type C (NPC) epidemiology trends @ Niemann-Pick Disease Type C (NPC) Epidemiology Forecast

Scope of the Niemann-Pick Disease Type C (NPC) Market Report

• Study Period: 2022-2036
• Coverage: 7MM (United States, EU4 [Germany, France, Italy, Spain], the United Kingdom, and Japan)
• Key Companies: IntraBio, Zevra Therapeutics, Cyclo Therapeutics, Azafaros, Beren Therapeutics, and others
• Key Therapies: AQNEURSA (levacetylleucine), MIPLYFFA (arimoclomol), TRAPPSOL CYCLO (Hydroxypropyl β-cyclodextrin), Nizubaglustat, Adrabetadex, Miglustat, and Standard of Care
• Market Dynamics: Drivers and Barriers
• Competitive Intelligence: SWOT Analysis, Conjoint Analysis, Market Forecast, Pricing, and Reimbursement
• **Patient Journey, KOL Views, Emerging Therapy

Assessment, and Epidemiology Analysis
To know more about Niemann-Pick Disease Type C (NPC) companies working in the treatment market, visit @ Niemann-Pick Disease Type C (NPC) Clinical Trials and Therapeutic Assessment

Table of Contents

• Niemann-Pick Disease Type C (NPC) Market Report Introduction
• Executive Summary
• Key Events
• Epidemiology and Market Methodology
• NPC Market Overview at a Glance
• Disease Background and Overview
• Classification of Niemann-Pick Disease
• Causes
• Inheritance Patterns
• Clinical Manifestations
• Pathophysiology
• Diagnosis
• Differential Diagnosis
• Diagnostic Algorithm
• Diagnostic Recommendations
• Treatment and Management
• Treatment Guidelines
• Epidemiology and Patient Population
• Patient Journey
• Marketed Therapies
• Emerging Therapies
• Seven Major Market Analysis
• Market Outlook
• Conjoint Analysis
• Market Forecast Assumptions
• Market Size by Country
• Market Size by Therapies
• Key Opinion Leader (KOL) Views
• SWOT Analysis
• Unmet Needs
• Market Access and Reimbursement
• Reimbursement Scenario in NPC
• Patient Access Programs
• Appendix
• Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Media Contact
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.